News | December 05, 2023
AstraZeneca discontinues Phase III trials of Stabilizer-CKD and Dialize-Outcomes
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
The receipt of this permission paves way for the launch of BREZTRI AEROSPHERE in India
Currently, Venkat is Lead – Market Access, India at Pfizer
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
Evinova will operate as a separate health-tech business within AstraZeneca
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Subscribe To Our Newsletter & Stay Updated
